Karo Healthcare completed the acquisition of Lamisil from Haleon for £235m.

Karo Healthcare, a European consumer healthcare company, completed the acquisition of Lamisil, a brand for the treatment of fungal infections like Athlete’s foot, from Haleon, a consumer healthcare company, for £235m. “We are pleased to add the global well-known and trusted brand, Lamisil, to our portfolio,” Christoffer Lorenzen, Karo CEO.